Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 2/20 | 0.62 |
| ▸ | CCR1 | P32246 | 10/20 | 0.59 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | DRD2 | P14416 | 1/20 | 0.54 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.54 |
| ▸ | IDO1 | P14902 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12874043 | 0.84 | QDPR (0.64) | QDPRCCR1MCHR1ALDH1A1DRD2 | |
| SCHEMBL7277302 | 0.84 | QDPR (0.69) | QDPRMCHR1ALDH1A1KCNH2 | |
| SCHEMBL16963363 | 0.84 | CCR1 (0.57) | CCR1DRD2HSD11B1IDO1KCNH2 | |
| SCHEMBL2098866 | 0.84 | HSD11B1 (0.58) | CCR1DRD2HSD11B1IDO1KCNH2 | |
| SCHEMBL11977020 | 0.83 | QDPR (0.59) | QDPRCCR1MCHR1ALDH1A1KCNH2 | |
| SCHEMBL15300836 | 0.83 | QDPR (0.62) | QDPRCCR1MCHR1ALDH1A1KCNH2 | |
| SCHEMBL7287663 | 0.83 | QDPR (0.62) | QDPRMCHR1ALDH1A1HSD11B1KCNH2 | |
| SCHEMBL10460507 | 0.83 | QDPR (0.62) | QDPRCCR1MCHR1KCNH2 | |
| SCHEMBL3080099 | 0.83 | QDPR (0.62) | QDPRCCR1MCHR1ALDH1A1KCNH2 | |
| SCHEMBL8060393 | 0.83 | DRD2 (0.54) | CCR1DRD2HSD11B1IDO1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | QDPR 331/4885CCR1 610/4885MCHR1 2667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.